Xenetic Biosciences, Inc. (XBIO)

NCM – Real Time Price. Currency in USD

3.02

-0.12 (-3.68%)

At close: May 12, 2026, 4:00 PM EDT

22.04.2026

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, IL. The accepted abstract, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," highlights preclinical research supporting Xenetic's DNase-based therapeutic approach designed to enhance CAR T-cell activity and improve antitumor responses.

13.03.2026

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and institutional collaborations Continued progress toward IND-enabling activities for DNase I program Ended the year with $7.9 million of cash to fund operations FRAMINGHAM, MA / ACCESS Newswire / March 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2025. Recent Highlights Expanded and presented preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and highlighting the therapeutic potential of Deoxyribonuclease (DNase) -based interventions; Progressed investigator-initiated exploratory studies in Israel evaluating DNase I in combination with standard-of-care and immunotherapy platforms, including: Ongoing pancreatic ductal adenocarcinoma (PDAC) study; Proposed large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor (CAR) T cell therapy; Advanced clinical manufacturing activities for DNase I toward Investigational New Drug (IND) application; Current focus on mechanism-of-action and translational research studies supported by encouraging CAR-T proof-of-concept studies with Scripps Research; and Pursuing strategic alternatives to maximize shareholder value.

11.12.2025

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting.

19.11.2025

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has executed a 4-month extension of its collaboration with The Scripps Research Institute ("Scripps Research") and the lab of Dr. Alexey Stepanov, Institute Investigator at Scripps Research effective November 1, 2025, to advance the development of the Company's research and development program evaluating the combination of systemic DNase I and CAR T-cell therapies. Xenetic's systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors.

13.11.2025

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS Newswire / November 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the third quarter 2025. "We are steadily building the foundation for potentially transformative progress in the oncology treatment paradigm as we advance our systemic DNase I program in combination with established cancer therapies," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

30.07.2025

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma.

23.07.2025

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its collaboration with The Scripps Research Institute ("TSRI") to advance the development of the Company's development program evaluating the combination of systemic DNase I and CAR T-cell therapies. Xenetic's systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors.

Videos

No Data

There is no data to display

Press releases

22.04.2026

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

13.03.2026

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

11.12.2025

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

19.11.2025

Xenetic Biosciences, Inc. (XBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Videos

No Data

Press releases

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Videos

No Data

Press releases

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Search stocks

Xenetic Biosciences, Inc. (XBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Videos

No Data

Press releases

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Videos

No Data

Press releases

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform